One of the most popular ADHD drugs may cause hallucinations and other psychotic symptoms

In the scientific article recently published in Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, Erica Ramstad and others reviewed the existing evidence between various psychotic symptoms such as hallucinations, problems with concentration or anxiety with methylphenidate, a drug commonly prescribed as a treatment for attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Methylphenidate is a stimulant that increases the activity of the central nervous system, helps to combat fatigue, improves attention and maintains alertness. Its medial use medical use began in 1960 and continues to grow since, reaching global consumption of 2.4 billion doses in 2013. Clinical studies confirmed safety and effectiveness of the drug and proved that its long-term usage reduces abnormalities in brain structure and function usually associated with ADHD syndrome.

Currently around around 5.3% children and adolescents worldwide suffer from ADHD condition. Psychostimulants, including methylphenidate, are first-choice drug treatment. Ramstad and others examined whether methylphenidate increases the risk of psychotic symptoms in children and adolescents affected with the illness. Although the amount and quality of existing data did not allow them to draw any strong conclusions, their research suggests that possible adverse symptoms may affect around 1.1% to 2.5% of ADHD patients treated with methylphenidate.

The article and its findings are of great importance for patients, physicians and caregivers who should be aware of possible adverse effects of the drug. In case of appearance of psychotic symptoms during the methylphenidate medication, clinicians should be able to address the problem, reduce or stop stimulant medication and ensure proper treatment.

Exeley Inc. a New York based company established in 2015 that focuses on offering innovative publishing services to Open Access publications worldwide.

The company is run by Dawid Cecula, an experienced manager in the publishing industry. In the last decade, Dawid has built one of the world’s largest collections of Open Access journals. He gained his experience from working for leading international publishers and delivering professional publishing and consulting services to universities, research centers and societies based in Europe, America and Asia.

Exeley Inc. offers journal owners a well-designed and technologically advanced publishing platform that integrates publications with online content, social media, databases and libraries. Users benefit from such solutions as: allocation of DOI numbers and live reference links via cooperation with Crossref; articles enhanced by graphical abstracts and extra supplementary files (including videos, sound files and power point presentations); advanced article metrics powered by PlumX, and responsive web design.

Exeley Inc.
https://www.exeley.com
347 Fifth Avenue,
Suite 1402-308
New York, NY 10016
(+1) 347 854 3245

This release was published on openPR.